

A DECLARATION OF JOINT WORKING

BETWEEN

Northern Lincolnshire and Goole NHS Foundation Trust

AND

ASTRAZENECA UK LTD

“Heart failure @home”

Executive In Put Summary

GB-48195

Executive Summary

Northern Lincolnshire and Goole NHS Foundation Trust and Astra Zeneca have entered a Joint working to undertake a CCG wide transformation of heart failure care in North Lincolnshire for both out-patient and inpatients commencing July 2021. Additional resource is being placed to support the Heart failure @ home project in the form of 2 heart failure nurses, consultant supervision and some admin support. The Joint working is part of a wider service supported by pharmacist, General Practitioner with Special Interest (GPwSi), and a recently commissioned database development. The entire programme is termed ‘The Connected Health Network’.

Hypotheses

- This programme is commissioned to reduce treatment gaps in heart failure patients ensuring maximum use of guideline indicated treatments, namely – Angiotensin Converting Enzyme inhibitors (ACE’s), Angiotensin II Receptor Beta Blockers (beta-blockers), Mineralocorticoid Receptor Antagonists & Angiotensin Receptor/ neprilysin inhibitor (MRA’s), and Sodium glucose co-transporter inhibitor – 2 (SGLT2i’s).

It is estimated that more than 4,000 patient appointments will be made available because of this project.

Benefit to the Patient

- The ability to reduce treatment gaps in heart failure patients ensuring maximum use of guideline indicated treatments namely – Angiotensin Converting Enzyme inhibitors (ACE’s), Angiotensin II Receptor Beta Blockers (beta-blockers), Mineralocorticoid Receptor Antagonists & Angiotensin Receptor/ neprilysin inhibitor (MRA’s), and Sodium glucose co-transporter inhibitor – 2 (SGLT2i’s).
- Increased accessibility to Heart Failure review for those patients who may struggle to access the existing services by offering remote appointments as well as face to face.
- Targeted appointment times, which will allow for more individualised care.
- Better Control of their condition by treatment within Local and National Guidelines and review by a Heart failure Specialist.
- More appropriate treatment to prevent progression of the disease and Prevention of Hospitalisations and ‘Enhanced patient education’.

Benefit to the NHS

- Common Guidelines
- Common databases with full interoperability
- Common budgets
- Seamless movement of patients at ‘click of a button’.
- Wide use of PCN pharmacists with input from consultants
- Collective investment in services rather than displacing costs to other Providers.
- Single clinical governance arrangement
- Overarching Governance

Benefit to Astra Zeneca

- The project will identify additional heart failure patients therefore the total market is expected to expand. AstraZeneca manufactures medicines for the treatment of heart failure and diabetes; therefore, the prescribing of these medicines may increase. This project is not reliant upon prescribing of AstraZeneca medicines and the decision to prescribe will remain with the clinician in line with local protocols and guidelines.
- Astra Zeneca will have access to anonymised data generated in the project.